Cargando…
Proteoglycan expression correlates with the phenotype of malignant and non-malignant EBV-positive B-cell lines
The involvement of proteoglycans (PGs) in EBV-host interactions and lymphomagenesis remains poorly investigated. In this study, expression of major proteoglycans (syndecan-1, glypican-1, perlecan, versican, brevican, aggrecan, NG2, serglycin, decorin, biglycan, lumican, CD44), heparan sulphate (HS)...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791248/ https://www.ncbi.nlm.nih.gov/pubmed/26527314 |
_version_ | 1782421053969006592 |
---|---|
author | Tsidulko, Alexandra Y. Matskova, Liudmila Astakhova, Lidiia A. Ernberg, Ingemar Grigorieva, Elvira V. |
author_facet | Tsidulko, Alexandra Y. Matskova, Liudmila Astakhova, Lidiia A. Ernberg, Ingemar Grigorieva, Elvira V. |
author_sort | Tsidulko, Alexandra Y. |
collection | PubMed |
description | The involvement of proteoglycans (PGs) in EBV-host interactions and lymphomagenesis remains poorly investigated. In this study, expression of major proteoglycans (syndecan-1, glypican-1, perlecan, versican, brevican, aggrecan, NG2, serglycin, decorin, biglycan, lumican, CD44), heparan sulphate (HS) metabolic system (EXT1/2, NDST1/2, GLCE, HS2ST1, HS3ST1/2, HS6ST1/2, SULF1/2, HPSE) and extracellular matrix (ECM) components (collagen 1A1, fibronectin, elastin) in primary B cells and EBV carrying cell lines with different phenotypes, patterns of EBV-host cell interaction and viral latency stages (type I-III) was investigated. Primary B cells expressed a wide repertoire of PGs (dominated by serglycin and CD44) and ECM components. Lymphoblastoid EBV+ B cell lines (LCLs) showed specific PG expression with down-regulation of CD44 and ECM components and up-regulation of serglycin and perlecan/HSPG2. For Burkitt's lymphoma cells (BL), serglycin was down-regulated in BL type III cells and perlecan in type I BL cells. The biosynthetic machinery for HS was active in all cell lines, with some tendency to be down-regulated in BL cells. 5′-aza-dC and/or Trichostatin A resulted in transcriptional upregulation of the genes, suggesting that low expression of ECM components, proteoglycan core proteins and HS biosynthetic system is due to epigenetic suppression in type I cells. Taken together, our data show that proteoglycans are expressed in primary B lymphocytes whereas they are not or only partly expressed in EBV-carrying cell lines, depending on their latency type program. |
format | Online Article Text |
id | pubmed-4791248 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-47912482016-03-28 Proteoglycan expression correlates with the phenotype of malignant and non-malignant EBV-positive B-cell lines Tsidulko, Alexandra Y. Matskova, Liudmila Astakhova, Lidiia A. Ernberg, Ingemar Grigorieva, Elvira V. Oncotarget Research Paper The involvement of proteoglycans (PGs) in EBV-host interactions and lymphomagenesis remains poorly investigated. In this study, expression of major proteoglycans (syndecan-1, glypican-1, perlecan, versican, brevican, aggrecan, NG2, serglycin, decorin, biglycan, lumican, CD44), heparan sulphate (HS) metabolic system (EXT1/2, NDST1/2, GLCE, HS2ST1, HS3ST1/2, HS6ST1/2, SULF1/2, HPSE) and extracellular matrix (ECM) components (collagen 1A1, fibronectin, elastin) in primary B cells and EBV carrying cell lines with different phenotypes, patterns of EBV-host cell interaction and viral latency stages (type I-III) was investigated. Primary B cells expressed a wide repertoire of PGs (dominated by serglycin and CD44) and ECM components. Lymphoblastoid EBV+ B cell lines (LCLs) showed specific PG expression with down-regulation of CD44 and ECM components and up-regulation of serglycin and perlecan/HSPG2. For Burkitt's lymphoma cells (BL), serglycin was down-regulated in BL type III cells and perlecan in type I BL cells. The biosynthetic machinery for HS was active in all cell lines, with some tendency to be down-regulated in BL cells. 5′-aza-dC and/or Trichostatin A resulted in transcriptional upregulation of the genes, suggesting that low expression of ECM components, proteoglycan core proteins and HS biosynthetic system is due to epigenetic suppression in type I cells. Taken together, our data show that proteoglycans are expressed in primary B lymphocytes whereas they are not or only partly expressed in EBV-carrying cell lines, depending on their latency type program. Impact Journals LLC 2015-10-16 /pmc/articles/PMC4791248/ /pubmed/26527314 Text en Copyright: © 2015 Tsidulko et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Tsidulko, Alexandra Y. Matskova, Liudmila Astakhova, Lidiia A. Ernberg, Ingemar Grigorieva, Elvira V. Proteoglycan expression correlates with the phenotype of malignant and non-malignant EBV-positive B-cell lines |
title | Proteoglycan expression correlates with the phenotype of malignant and non-malignant EBV-positive B-cell lines |
title_full | Proteoglycan expression correlates with the phenotype of malignant and non-malignant EBV-positive B-cell lines |
title_fullStr | Proteoglycan expression correlates with the phenotype of malignant and non-malignant EBV-positive B-cell lines |
title_full_unstemmed | Proteoglycan expression correlates with the phenotype of malignant and non-malignant EBV-positive B-cell lines |
title_short | Proteoglycan expression correlates with the phenotype of malignant and non-malignant EBV-positive B-cell lines |
title_sort | proteoglycan expression correlates with the phenotype of malignant and non-malignant ebv-positive b-cell lines |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791248/ https://www.ncbi.nlm.nih.gov/pubmed/26527314 |
work_keys_str_mv | AT tsidulkoalexandray proteoglycanexpressioncorrelateswiththephenotypeofmalignantandnonmalignantebvpositivebcelllines AT matskovaliudmila proteoglycanexpressioncorrelateswiththephenotypeofmalignantandnonmalignantebvpositivebcelllines AT astakhovalidiiaa proteoglycanexpressioncorrelateswiththephenotypeofmalignantandnonmalignantebvpositivebcelllines AT ernbergingemar proteoglycanexpressioncorrelateswiththephenotypeofmalignantandnonmalignantebvpositivebcelllines AT grigorievaelvirav proteoglycanexpressioncorrelateswiththephenotypeofmalignantandnonmalignantebvpositivebcelllines |